Toxicity management for patients receiving novel T-cell engaging therapies.

ABSTRACT:

Purpose of review

Recent clinical trials using T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cells, as well as engineered T cells that express targeting and activation molecules known as chimeric antigen receptors, have demonstrated powerful proof of concept. These therapies result in a significant degree of immune activation in the patient, which has correlated with greatly increased efficacy but also with notable toxicity. These therapies produce nonphysiologic T-cell activation, which is the hallmark of these new, highly active treatments.

Recent findings

We and others have noted cytokine activation profiles that correlate with both toxicity and efficacy in patients receiving T-cell engaging therapies. Effector cytokines such

SUBMITTER: Barrett DM 

PROVIDER: S-EPMC4198063 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature